Estudo retrospectivo e comparativo de quarenta e três olhos com hidropisia aguda em quinhentos e sessenta e sete casos de ceratocone

Pena, Frederico Valadares de Souza; Pena, Ari de Souza; Araújo, Patrícia Garcia de

doi:10.1590/s0004-27492003000100008

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past years, psychiatrists have had a majority of the prescribing and independent practice rights and have been the primary target of pharmaceutical marketing efforts [ 36 ]. Nevertheless, PAs and NPs are gaining independent prescribing rights across the country despite the fact that regulations concerning physician-pharmaceutical interactions mainly target physicians [ 37 , 38 ]. If trends with NPs and PAs follow what this study has found about physicians, policy and regulations concerning pharmaceutical promotions should address all providers, not just physicians.…”

Section: Discussionmentioning

confidence: 99%

Patterns and predictors of off-label prescription of psychiatric drugs

2018

View full text Add to dashboard Cite

Off-label prescribing of psychiatric drugs is common, despite lacking strong scientific evidence of efficacy and potentially increasing risk for adverse events. The goal of this study was to characterize prevalence of off-label prescriptions of psychiatric drugs and examine patient and clinician predictors of off-label use. This manuscript presents a retrospective, cross-sectional study using data from the 2012 and 2013 National Ambulatory Medical Care Surveys (NAMCS). The study examined all adult outpatient visits to psychiatric practices for chronic care management with a single listed visit diagnosis in which at least one psychiatric drug was prescribed. The main outcome measure was off-label prescribing of at least one psychiatric drug, defined as prescription for a condition for which it has not been approved for use by the FDA. Among our sample representative of 1.85 billion outpatient visits, 18.5 million (1.3%) visits were to psychiatrists for chronic care management in which at least one psychiatric drug was prescribed. Overall, the rate of off-label use was 12.9% (95% CI: 12.2–15.7). The most common off-label uses were for manic-depressive psychosis treated with citalopram and primary insomnia treated with trazodone. Several patient and clinician characteristics were positively associated with off-label prescribing, including seeing a psychiatrist (OR: 1.06, 95% CI, 1.01–1.12; p = 0.03) instead of another type of clinician, the office visit taking place in the Western region of the country (OR: 1.09, 95% CI, 1.01–1.17; p = 0.02), and the patient having 3 or more chronic conditions (OR: 1.12, 95% CI, 1.02–1.14; p = 0.003). In contrast, having Medicare coverage (OR: 0.93, 95% CI, 0.84–0.97; p = 0.04) and receiving payment assistance from a medical charity (OR: 0.91, 95% CI, 0.88–0.96; p = 0.03) instead of private insurance were negatively associated with off-label prescribing. These results suggest that certain classes of psychiatric medications are being commonly prescribed to treat conditions for which they have not been determined by the FDA to be clinically efficacious and/or safe.

show abstract

Section: Discussionmentioning

confidence: 99%